Company: STAA
Filing Date: 2025-10-30
Form Type: DEFA14A
Source: 0001193125-25-258558
Chunk: 27

Company: STAAR SURGICAL CO
Filing Date: 2025-10-30
Form: DEFA14A
Chunk 27
---
 |   999 |     |           | 0.9x |
| RxSight, Inc.              |     | $                |    96 |     |           | 0.7x |

16

Based on its professional judgment and experience, and taking into consideration the observed multiples for the selected companies, Citi then applied an illustrative EV / 2026E Revenue multiple reference range of 1.9x to 3.1x to an estimate of STAAR’s 2026 revenue based on the Projections, to derive ranges of implied enterprise value for STAAR. To the range of implied enterprise values it derived for STAAR, Citi added STAAR’s net cash of $185 million as of June 27, 2025 and divided the results by the diluted common stock share count of STAAR, calculated using the treasury stock method, based on equity information as of July 30, 2025 as provided by STAAR management. This analysis indicated an approximate implied per share equity value reference range for STAAR of $16.35 to $23.80, as compared to the closing share price of the STAAR common stock as of August 1, 2025, of $17.76, and the Merger Consideration of $28.00. The section titled “—Selected Precedent Transactions Analysis” beginning on page 56 of the proxy statement is hereby amended and supplemented as follows: Using publicly available information, Citi performed a selected precedent transactions analysis of STAAR in which Citi reviewed financial data relating to the followingseven selected transactions listed in the table belowthat Citi considered generally relevant for purposes of analysis, which are collectively referred to as the “selected transactions” . :

| Announcement Date |     | Acquiror                      |     | Target                       |
| 03/24/2025        |     | Alcon Inc.                    |     | LENSAR, Inc.                 |
| 06/18/2024        |     | Boston Scientific Corporation |     | Silk Road Medical, Inc.      |
| 02/09/2023        |     | Abbott Laboratories           |     | Cardiovascular Systems, Inc. |
| 01/12/2021        |     | STERIS plc                    |     | Cantel Medical Corp.         |
| 12/18/2020        |     | Koninklijke Philips N.V.      |     | BioTelemetry, Inc.           |
| 11/04/